 Connection
Andrew Getahun to Antibodies, Monoclonal
This is a "connection" page, showing publications Andrew Getahun has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.151 |
|
|
|
-
Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 12; 43:39-45.
Score: 0.086
-
Wemlinger SM, Parker Harp CR, Yu B, Hardy IR, Seefeldt M, Matsuda J, Mingueneau M, Spilker KA, Cameron TO, Larrick JW, Getahun A, Cambier JC. Preclinical Analysis of Candidate Anti-Human CD79 Therapeutic Antibodies Using a Humanized CD79 Mouse Model. J Immunol. 2022 04 01; 208(7):1566-1584.
Score: 0.031
-
Hardy IR, Anceriz N, Rousseau F, Seefeldt MB, Hatterer E, Irla M, Buatois V, Chatel LE, Getahun A, Fletcher A, Cons L, Pontini G, Hertzberg NA, Magistrelli G, Malinge P, Smith MJ, Reith W, Kosco-Vilbois MH, Ferlin WG, Cambier JC. Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol. 2014 Feb 15; 192(4):1641-50.
Score: 0.018
-
Rutemark C, Alicot E, Bergman A, Ma M, Getahun A, Ellmerich S, Carroll MC, Heyman B. Requirement for complement in antibody responses is not explained by the classic pathway activator IgM. Proc Natl Acad Sci U S A. 2011 Oct 25; 108(43):E934-42.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|